What Was Approved?
On October 7, 2025, the U.S. Food and Drug Administration approved Jascayd (nerandomilast) for the treatment of idiopathic pulmonary fibrosis, or IPF, in adults.
Jascayd was the first new FDA-approved treatment for IPF in more than 10 years.
What Is Idiopathic Pulmonary Fibrosis?
IPF is a chronic lung disease in which lung tissue becomes progressively scarred and stiff.
This scarring can make breathing more difficult over time and may lead to symptoms such as:
- Shortness of breath
- Persistent cough
- Reduced exercise tolerance
The rate of progression can vary from one patient to another.
How Does Jascayd Work?
Jascayd is a phosphodiesterase 4, or PDE4, inhibitor.
It is designed to reduce signaling involved in inflammation and fibrosis in the lungs.
How Is Jascayd Taken?
The recommended dose is:
18 mg by mouth twice daily, approximately 12 hours apart, with or without food.
For some patients who cannot tolerate the 18 mg dose, the prescribing information allows a reduction to 9 mg twice daily, with specific exceptions depending on other medications.
What Are Common Side Effects?
Common adverse reactions include:
- Diarrhea
- Decreased appetite
- Weight loss
- Nausea
Other adverse effects may also occur.
Does Jascayd Cure IPF?
No.
IPF is a chronic, progressive lung disease, and Jascayd should not be described as a cure.
The goal of treatment is to help slow disease progression and preserve lung function as much as possible.
Bottom Line
Jascayd (nerandomilast) is an FDA-approved oral treatment for adults with idiopathic pulmonary fibrosis.
It is taken twice daily and represents a new treatment option for a serious progressive lung disease, but it does not cure IPF and requires ongoing medical follow-up.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves Drug to Treat Idiopathic Pulmonary Fibrosis, October 7, 2025.
- U.S. Food and Drug Administration (FDA) — Jascayd (nerandomilast) Prescribing Information.
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2025.